# A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

> **NCT07325136** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 240 (estimated)

## Conditions studied

- Relapsed/Refractory Small Cell Lung Cancer

## Interventions

- **DRUG:** BMS-986525
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07325136
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-03
- **Primary completion:** 2029-04-23
- **Final completion:** 2029-04-24
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07325136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07325136, "A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT07325136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*